Peptide-based radiopharmaceutical developer Diatide reported last week that the Food and Drug Administration has accepted the company's new drug application (NDA) filing for AcuTect, and has placed the NDA under priority review status. The FDA reserves
Peptide-based radiopharmaceutical developer Diatide reported last week that the Food and Drug Administration has accepted the company's new drug application (NDA) filing for AcuTect, and has placed the NDA under priority review status. The FDA reserves priority review for products that could be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious or life-threatening disease, according to Londonderry, NH-based Diatide. Receipt of the status means that the review time for AcuTect will most likely be cut in half, with the FDA completing its review in six months. AcuTect is designed for the detection of acute venous thrombosis (SCAN 9/3/97).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.